

GSK plc (the 'Company')
Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.6153	10 (partnership shares)
		£12.6153	10 (matching shares)
d)	Aggregated information		
	Aggregated volume	20 Ordinary Shares	
	Price	£12.6153	
e)	Date of the transaction	2025-04-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification

	amendment		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.6153	10 (partnership shares)
		£12.6153	10 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	20 Ordinary Shares £12.6153	
e)	Date of the transaction	2025-04-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.6153	10 (partnership shares)

		£12.6153	10 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	20 Ordinary Shares £12.6153	
e)	Date of the transaction	2025-04-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communications and CEO Office	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.6153	10 (partnership shares)
		£12.6153	10 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	20 Ordinary Shares £12.6153	
e)	Date of the transaction	2025-04-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	David Redfern	
b)	Position/status	President, Corporate Development	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.6153	10 (partnership shares)
		£12.6153	10 (matching shares)
d)	Aggregated information		
	Aggregated volume	20 Ordinary Shares	
	Price	£12.6153	
e)	Date of the transaction	2025-04-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the	Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

	financial instrument	ISIN: GB00BN/SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.6153	10 (partnership shares)
		£12.6153	10 (matching shares)
d)	Aggregated information		
	Aggregated volume	20 Ordinary Shares	
	Price	£12.6153	
e)	Date of the transaction	2025-04-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.6153	10 (partnership shares)
		£12.6153	10 (matching shares)
d)	Aggregated information		
	Aggregated volume	20 Ordinary Shares	
	Price	£12.6153	
e)	Date of the transaction	2025-04-09	
f)	Place of the transaction	London Stock Exchange (LON)	

1)	Place of the transaction	LONDON STOCK EXCHANGE (XLON)
----	--------------------------	------------------------------

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.6153	10 (partnership shares)
		£12.6153	10 (matching shares)
d)	Aggregated information		
	Aggregated volume	20 Ordinary Shares	
	Price	£12.6153	
e)	Date of the transaction	2025-04-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc

a)	NAME	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ("Ordinary Shares") ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.6153	10 (partnership shares)
		£12.6153	10 (matching shares)
d)	Aggregated information		
	Aggregated volume	20 Ordinary Shares	
	Price	£12.6153	
e)	Date of the transaction	2025-04-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £13.1269	Volume(s) 35
d)	Aggregated information	N/A (single transaction)	

	Aggregated volume Price	
e)	Date of the transaction	2025-04-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Diana Conrad	
b)	Position/status	Chief People Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £13.1269	Volume(s) 7
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-04-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	

	amendment		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £13.1269	Volume(s) 11
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-04-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communications and CEO Office	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£13.1269	22

d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2025-04-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Luke Miels	
b)	Position/status	Chief Commercial Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £13.1269	Volume(s) 3
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-04-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	David Redfern
b)	Position/status	President Corporate Development

c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on shares held through the Company's Share Reward Plan				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£13.1269</td><td>91</td></tr></table>	Price(s)	Volume(s)	£13.1269	91
Price(s)	Volume(s)					
£13.1269	91					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2025-04-10				
f)	Place of the transaction	London Stock Exchange (XLON)				

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Regis Simard	
b)	Position/status	President, Global Supply Chain	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)

		£13.1269	35
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-04-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) £13.1269	Volume(s) 59
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-04-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Deborah Waterhouse

b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on shares held through the Company's Share Reward Plan		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£13.1269	76	
d)	Aggregated information Aggregated volume Price	N/A (single transaction)		
e)	Date of the transaction	2025-04-10		
f)	Place of the transaction	London Stock Exchange (XLON)		

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025 on shares held through the Company's Share Reward Plan

c)	Price(s) and volume(s)	Price(s) £13.1269	Volume(s) 70
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-04-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dylan Jackson	
b)	Position/status	PCA of Ms S Jackson (SVP, Global Communications and CEO Office)	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025.	
c)	Price(s) and volume(s)	Price(s) £13.0668	Volume(s) 1
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-04-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Victoria Whyte

b)	Position/status	Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025.	
c)	Price(s) and volume(s)	Price(s) £13.0668	Volume(s) 20
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-04-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Iain Whyte	
b)	Position/status	PCA of Ms V Whyte (Company Secretary)	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)

		£13.0668	1,414
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-04-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSFMDFEISED L